Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    Belcesiran aat

Study of DCR-A1AT in Healthy Adult Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04174118
Recruitment Status : Recruiting
First Posted : November 22, 2019
Last Update Posted : February 1, 2021
Sponsor:
Information provided by (Responsible Party):
Dicerna Pharmaceuticals, Inc.

Brief Summary:

This is a research study to test an experimental study drug (belcesiran, also known as DCR-A1AT). This drug is being tested to see if it helps people with a rare condition known as Alpha-1 Antitrypsin Deficiency, or A1ATD. Prior to initiation of this study belcesiran had not yet been tested in humans. All study participants will be randomly assigned to either receive the study drug or a placebo. This will allow for the sponsor to compare the effects of the study drug with that of the placebo. A placebo looks like the study drug but does not contain any of the study drug.

The main purpose of the first part of the study is to evaluate the safety profile of the study drug in people who do not have A1ATD. This part of the study will also help find the dose of the study drug that has an acceptable safety profile for testing.


Condition or disease Intervention/treatment Phase
Alpha 1-Antitrypsin Deficiency Drug: belcesiran Drug: Placebo Phase 1

Detailed Description:

A1ATD- associated liver disease is a progressive Alpha-1 Antitrypsin-Deficiency Associated Liver Disease condition resulting in liver fibrosis, cirrhosis, and hepatocellular carcinoma. The lack of functional A1AT in individuals with PiZZ genotype, in conjunction with other precipitating factors, can lead to unchecked activity in neutrophil elastases in the alveoli; causing emphysema and chronic obstructive pulmonary disease (COPD). This loss-of-function mechanism can be addressed with intravenous augmentation therapy, which aims to substitute the missing A1AT by infusing alpha1 proteinase inhibitor (A1PI), purified from pooled human plasma.

While augmentation therapy can address the loss of A1AT in the lungs, no treatment exists for the associated liver disease.

Given the severity of the disease, with approximately 10% of affected patients developing liver cirrhosis and a subgroup of those patients in need of liver transplantation, and lack of an effective treatment that addresses the toxic hepatic "gain-of-function" mechanism, there is an urgent unmet medical need to develop a therapy that can help in this particular patient population.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Double-Blind
Primary Purpose: Other
Official Title: A Phase 1 Single Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered Belcesiran in Healthy Adult Volunteers
Actual Study Start Date : October 24, 2019
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : June 2022


Arm Intervention/treatment
Experimental: belcesiran
Healthy volunteers will be administered a single dose of belcesiran.
Drug: belcesiran
belcesiran will be administered subcutaneously (SC) at dose levels planned.

Placebo Comparator: Placebo
Healthy volunteers will be administered a single dose of matching placebo.
Drug: Placebo
Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).




Primary Outcome Measures :
  1. Safety and tolerability [ Time Frame: approximately up to 2 months ]
    The incidence of adverse events (AE), serious adverse events (SAE), DLT, and AE leading to study drug discontinuation

  2. Evaluating safety and tolerability through physical exams [ Time Frame: approximately up to 2 months ]
    The incidence of clinically significant physical examination (PE) findings

  3. Changes in 12-lead electrocardiograms (ECG) [ Time Frame: approximately up to 2 months ]
    Absolute QTc > 500 msec and/or QTc change of > 60 msec from baseline will be evaluated


Secondary Outcome Measures :
  1. Urine pharmacokinetics (PK) of belcesiran [ Time Frame: up to Day 3 ]
    Maximum observed concentration (Cmax)

  2. Plasma pharmacokinetics (PK) of belcesiran [ Time Frame: up to 57 days ]
    Maximum observed concentration (Cmax)

  3. Plasma pharmacokinetics (PK) of belcesiran [ Time Frame: up to 57 days ]
    Area under the curve (AUC)

  4. Urine pharmacokinetics (PK) of belcesiran [ Time Frame: up to Day 3 ]
    Area under the curve (AUC)

  5. Urine pharmacokinetics (PK) of belcesiran [ Time Frame: up to Day 3 ]
    Minimum observed concentration (Cmin)

  6. Plasma pharmacokinetics (PK) of belcesiran [ Time Frame: up to 57 days ]
    Minimum observed concentration (Cmin)

  7. Plasma pharmacokinetics (PK) of belcesiran [ Time Frame: up to 57 days ]
    Time to maximum concentration (Tmax)

  8. Urine pharmacokinetics (PK) of belcesiran [ Time Frame: up to Day 3 ]
    Time to maximum concentration (Tmax)

  9. Urine pharmacokinetics (PK) of belcesiran [ Time Frame: up to Day 3 ]
    Terminal elimination half-life (t1/2)

  10. Plama pharmacokinetics (PK) of belcesiran [ Time Frame: up to 57 days ]
    Terminal elimination half-life (t1/2)

  11. Change in protein concentration [ Time Frame: up to day 57 ]
    Changes in A1AT protein concentrations



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or Female aged 18 to 55 years, inclusive. Female participants must be either surgically sterile or postmenopausal. No women of childbearing potential are eligible for enrollment.
  • Overtly Healthy, as determined by the investigator.
  • Serum A1AT protein concentration >100 mg/dL
  • Adequate forced expiratory volume in one second (FEV1) and adequate FEV1/forced vital capacity (FVC) ratio
  • Non-smokers with a <2 pack-year history and smoking cessation for at least 6 months with a negative urinary cotinine test a screening

Exclusion Criteria:

  • Presence of any condition or comorbidities that would interfere with study compliance or data interpretation or potentially affect participant safety
  • Clinically significant abnormal laboratory tests
  • Received an experimental drug within past 4 months
  • Prior to use of RNAi drug or oligonucleotide-based therapy
  • Known human immunodeficiency virus (HIV), hepatitis C virus (HCV), or Hepatitis B (HBV)
  • Serum creatinine or estimated glomerular filtration rate (eGFR) outside normal reference ranges.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04174118


Contacts
Layout table for location contacts
Contact: Dicerna Pharmaceuticals 617-621-8097 medicalinfo@dicerna.com

Locations
Layout table for location information
New Zealand
Auckland Clinical Studies Recruiting
Grafton, Auckland, New Zealand, 1010
Contact: Ed Gane, MD    +64 9 3733474      
Sweden
Clinical Trial Consultants AB Completed
Uppsala, Sweden
Sponsors and Collaborators
Dicerna Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Hardean Achneck, MD Dicerna Pharmaceuticals
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dicerna Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT04174118    
Other Study ID Numbers: DCR-A1AT-101
First Posted: November 22, 2019    Key Record Dates
Last Update Posted: February 1, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alpha 1-Antitrypsin Deficiency
Liver Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Subcutaneous Emphysema
Emphysema
Pathologic Processes